Chronic Limb-Threatening Ischemia
36
13
18
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 36 trials
100.0%
+13.4% vs benchmark
3%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (36)
Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study
IVUS Guidance in BTK Interventions
Pivotal Trial of the Boomerang Catheter for pDVA
Colchicine in Chronic Limb-Threatening Ischemia
REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
ORbital Atherectomy for Lesion Preparation in Patients With Chronic Limb-threatening ischEmia
Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study
AcoArt Litos PCB Below-the-knee Global Trial
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia
Woundsome Revascularization in Chronic Limb-Threatening Ischemia
Esprit BTK Post-Approval Study
Structured Educational Program vs Standard Care in Pre-surgical Critical Limb Ischemia Patients
Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia
Chronic Wounds and Blood Circulation Detection
Pressure Wire Guidance for Infrapopliteal Artery Interventions
Peripheral Bypass Trial for Completion Control
The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)
The ROAMM-EHR Study